AIEQ1.630%
as of Jul 20
INCY
GrowthINCYTE CORPORATION.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Close · 3M
+19.10%
Held by 2 AI ETFs
QRFT0.060%
as of Jul 8
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals4
Win rate75% (3/4)
Avg buy return+7.26%
AIEQ · Weight increase · 2d
After a minor dip, AIEQ showed a gradual, consecutive weight increase for Incyte, adding 0.03% then 0.02% on successive days. This move, occurring as the Health Care stock trades at 99% of its 52-week high after a +74.3% one-year return, reflects the fund's specific methodology. IBM Watson's NLP likely processed new, reinforcing positive sentiment signals from news, social posts, or analyst notes, overriding any price-level caution. Bolstered by the company's 21.48% revenue growth and 29.2% ROE, EquBot's risk overlay permitted these additions, showcasing its fundamentals-plus-sentiment hybrid approach within its daily rebalancing framework.
weight 1.580% → 1.630% (+0.050 pp)·stock up 17.5% in the 30 days before
Jul 19·entry $115.65·now $115.65Fresh
0.00%
since Jul 19
AIEQ · Weight decrease · 2d
Incyte Corporation's PBR of 3.75, Revenue Growth of 21.48%, and ROE of 29.2% align with the fundamental criteria used by AIEQ's manager, Amplify ETFs (EquBot). However, AIEQ's methodology, powered by IBM Watson's NLP ingesting vast data daily, combines these fundamentals with sentiment analysis. The consecutive weight decrease in INCY, moving from 1.61% to 1.58% between July 11 and July 15, indicates that the system likely detected a shift in sentiment or increased risk, particularly as the stock was trading at $115.09, near 97% of its 52-week high after a +24.8% 30-day return. This prompt adjustment reflects AIEQ's high-turnover portfolio and daily rebalancing, allowing it to react swiftly to nuanced signals.
weight 1.610% → 1.580% (-0.030 pp)·stock up 6.0% in the 30 days before
Jul 15·entry $115.09·now $115.65
+0.49%
since Jul 15
AIEQ · Weight decrease · 2d
Incyte is currently trading at $116.71, just below its 52-week high of $118.52, having seen a 70.7% return over the past year. This position near the top of its range interacts directly with AIEQ's strategy, which relies on IBM Watson's NLP for daily rankings and EquBot's risk overlay for frequent portfolio adjustments in its high-turnover, sentiment-hybrid approach. Despite strong financials like 21.48% revenue growth and 29.2% ROE, AIEQ tactically reduced its exposure in the healthcare company, as evidenced by weight adjustments from 1.6300% to 1.6100% on July 7th and again to 1.6100% on July 11th. This shift suggests Watson's continuous ingestion of news and social posts likely identified evolving short-term sentiment or increased risk associated with Incyte's elevated valuation after its significant rally, prompting the fund to trim its position.
weight 1.650% → 1.610% (-0.040 pp)·stock up 13.1% in the 30 days before
Jul 11·entry $114.23·now $115.65
+1.24%
since Jul 11
AIEQ · Weight increase · 2d
AIEQ's AI-driven strategy, managed by Amplify ETFs, initiated and then increased its position in Incyte Corporation due to signals processed by IBM Watson NLP. This system, which ingests news, filings, and social posts daily, likely detected a substantial shift in the narrative or analyst sentiment surrounding the Health Care company. Operating with a daily rebalancing cadence across its 140-180 US stocks, AIEQ swiftly moved from a 0% holding to 1.56% then 1.63% for INCY. The AI's ranking, which combines fundamentals and sentiment, would have found support in Incyte's 29.2% Return on Equity and its 21.48% revenue growth. This move happened as the stock achieved 100% of its 52-week high, following a 70.7% 1-year return, indicating the AI's algorithm integrated both strong underlying financials and prevailing positive market momentum.
weight 0 → 1.630% (new)·stock up 26.7% in the 30 days before
Jul 3·entry $115.62·now $115.65Fresh
+0.03%
since Jul 3
AIEQ · New entry · 1d
Amplify ETFs' AIEQ, which rebalances its 140-180 stock portfolio daily, added Incyte Corporation (INCY) to its holdings on July 1, 2026, allotting it a 1.5600% weight. This daily adjustment is driven by IBM Watson NLP processing news, filings, and social posts to derive a daily ranking of US equities, reflecting the fund's broad market, fundamentals-plus-sentiment hybrid style. The AI's analysis likely flagged positive shifts for the Health Care company, particularly as it trades near 99% of its 52-week high after a 66.7% one-year return. This inclusion suggests the system identified compelling signals, potentially factoring in the company's 21.48% revenue growth as a fundamental catalyst alongside detected sentiment improvements.
weight 0 → 1.560% (new)·stock up 19.1% in the 30 days before
Jul 1·entry $113.81·now $115.65Fresh
+1.62%
since Jul 1
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Too hard to callas of Jul 12
AI ETFs initially showed interest in Incyte, with AIEQ entering and increasing its weight, but then a recent weight decrease trend emerged. This shifting AI sentiment contrasts with the framework's 'Too Hard' verdict, which suggests avoiding the company altogether due to the fundamental unpredictability of its industry rather than reacting to short-term trends.
- Circle of CompetenceThe biotechnology industry's inherent unpredictability regarding drug discovery, regulatory approvals, and patent expirations makes long-term cash flow projections unreliable for this framework.
- Economic MoatA full assessment of an economic moat is not performed as the company fails the circle of competence stage.
- ManagementA full assessment of management is not performed as the company fails the circle of competence stage.
- Financial HealthA full assessment of financial health is not performed as the company fails the circle of competence stage.
- Margin of SafetyA full assessment of margin of safety is not performed as the company fails the circle of competence stage.
Incyte Corporation operates in the biotechnology sector, a domain characterized by high R&D risk, regulatory uncertainties, and patent cliffs that make long-term cash flow predictability extremely challenging. Within a Buffett-style framework, this business environment falls outside the circle of competence, making it impossible to reliably project future earning power. Therefore, the company is deemed 'Too Hard' to evaluate, regardless of its current financial performance or valuation metrics.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.